Valuation: Alligator Bioscience AB

Market Cap 112M 11.57M 10.12M 9.34M 8.62M 16.36M 1.1B 16.64M 43.81M 544M 43.45M 42.5M 1.87B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 112M 11.57M 10.12M 9.34M 8.62M 16.36M 1.1B 16.64M 43.81M 544M 43.45M 42.5M 1.87B EV / Sales 2026 *
2.8x
EV / Sales 2027 * 18.9x
Free-Float
71.01%
Yield 2026 *
-
Yield 2027 * -
1 day-0.56%
1 week-3.27%
Current month+2.07%
1 month-0.56%
3 months-1.44%
6 months-63.76%
Current year-47.28%
1 week 0.17
Extreme 0.1704
0.19
1 month 0.16
Extreme 0.1596
0.19
Current year 0.16
Extreme 0.157
0.49
1 year 0.16
Extreme 0.157
6.04
3 years 0.16
Extreme 0.157
1,568
5 years 0.16
Extreme 0.157
7,200
10 years 0.16
Extreme 0.157
40,100
Manager TitleAgeSince
Chief Executive Officer 55 2021-05-31
Director of Finance/CFO 61 2024-08-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 2021-05-31
Director/Board Member 68 2022-05-08
Date Insider Type Main position Quantity % Market Cap.
25-03-04Buy

Chairman

800,000 0.0047%
25-03-04Buy

Chairman

77,319 0.0005%
25-03-04Sell

Chairman

1,658,134 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-3.27%-96.75%-99.96% 11.57M
+0.58%+2.06%+3.90%+10.40% 50.73B
-2.22%-1.25%+391.53%+591.38% 39.73B
-0.54%+0.39%+27.67%-3.89% 34.69B
-1.36%+0.35%+19.34%+58.83% 33.21B
+1.21%-4.58%+3.00%+37.03% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+125.61% 15.37B
+0.23%-0.58%+13.80%+19.56% 13.78B
-0.62%-3.09%+11.43%-29.93% 12.85B
Average -0.46%-1.07%+48.92%+78.78% 24.39B
Weighted average by Cap. -0.48%-0.23%+82.74%+126.13%

Financials

2026 *2027 *
Net sales 39.9M 4.14M 3.62M 3.34M 3.08M 5.85M 395M 5.95M 15.67M 194M 15.54M 15.2M 669M 5.9M 612K 535K 494K 456K 865K 58.37M 880K 2.32M 28.76M 2.3M 2.25M 98.86M
Net income -36.3M -3.77M -3.29M -3.04M -2.81M -5.32M -359M -5.41M -14.26M -177M -14.14M -13.83M -608M -69.9M -7.25M -6.34M -5.85M -5.4M -10.25M -692M -10.42M -27.45M -341M -27.23M -26.63M -1.17B
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
26-07-10 SEK 0.1776 -0.56% 814,123
26-07-09 SEK 0.1786 +0.22% 764,718
26-07-08 SEK 0.1782 -1.00% 1,244,844
26-07-07 SEK 0.1800 -1.64% 925,403
26-07-06 SEK 0.1830 -0.33% 1,517,346
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATORX Stock